Back to discover
Drug

Erythromycin

Regulatory activity · MHRA
ClassBacterial 70S ribosome inhibitorEmerging researchLate-stage development
Also known as Abomacetin, Aktipak, E-Solve 2, E.E.S.+48 more

Abomacetin, Aktipak, E-Solve 2, E.E.S., Emcin Clear, Emgel, Eritromicina, Ery, Ery-Sol, Ery-Tab, EryPed, Eryc, Erycette, Eryderm, Erygel, Erymax, Erythra-Derm, Erythrocin Stearate, Erythrocot, Erythromycin Base, Erythromycin Estolate, Erythromycin Lactobionate, Erythromycin Stearate, Erythromycin Topical, Erythromycin, Ophthalmic, Eryzole, Ilosone, Ilotycin, MY-E, Maracyn, Staticin, T-Stat, 3''-O-demethylerythromycin, Akne-Mycin, Benzamycin, Benzoyl Peroxide-Erythromycin, Del-Mycin, E-Mycin, Erythromycin-Sulfisoxazole, Eyemycin, Pediazole, Robimycin, Romycin, Sulfimycin, Theramycin, Erythrocin, Erythromycin A, Erythromycin ES, érythromycine, A/T/S, Erythromycin Ethylsuccinate, Erythromycinum.

1
Research papers
4
Active clinical trials
55
Protein targets
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy

Clinical trial2026-01-27Results expected Q4 2026 · ClinicalTrials.gov

Platform for Adaptive Trials in Perinatal Units (Core Protocol)

Clinical trial2025-06-13Results expected Q4 2050 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Erythromycin
Aliases & brands
AbomacetinAktipakE-Solve 2E.E.S.Emcin ClearEmgelEritromicinaEryEry-SolEry-TabEryPedErycErycetteErydermErygelErymaxErythra-DermErythrocin StearateErythrocotErythromycin BaseErythromycin EstolateErythromycin LactobionateErythromycin StearateErythromycin TopicalErythromycin, OphthalmicEryzoleIlosoneIlotycinMY-EMaracynStaticinT-Stat3''-O-demethylerythromycinAkne-MycinBenzamycinBenzoyl Peroxide-ErythromycinDel-MycinE-MycinErythromycin-SulfisoxazoleEyemycinPediazoleRobimycinRomycinSulfimycinTheramycinErythrocinErythromycin AErythromycin ESérythromycineA/T/SErythromycin EthylsuccinateErythromycinum
RxNorm CUI
4053
ChEMBL ID
CHEMBL532
ATC codes
S01AA17J01FA01D10AF02D10AF52
UNII
63937KV33D
Primary mechanism
Bacterial 70S ribosome inhibitor
Regulatory jurisdictions
mhra

Pharmacology & targets

55 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
2
mhraMedicines and Healthcare products Regulatory Agency· 2 events
2020-12-17Safety communicationSafety
Drug Safety Update: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
Evidence ↗
2020-12-17Safety communicationSafety
Drug Safety Update: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

56 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
56
registered trials across all phases
LATEST COMPLETION 2025
4
Active studies
3
Recruiting
34
Late-stage (III+)
35
Completed
17
Discontinued
PHASE DISTRIBUTIONn = 56
Phase 114Phase 1 / 21Phase 27Phase 2 / 32Phase 37Phase 49Phase N / A16

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes4
Pneumococcal Infections1Pneumococcal Vaccines1Streptococcus pneumoniae1Vaccines, Conjugate1
Journals, researchers & institutions
Top journals
  • Nature communications1
Leading researchers
  • Bentley SD1
  • Chochua S1
  • Cohen C1
  • de Gouveia L1
  • du Plessis M1
  • Ferreira ADS1
  • Gladstone RA1
  • Hawkins PA1
Leading institutions
free-text, unnormalised
  • Centers for Disease Control and Prevention1
  • Centre for Respiratory Diseases and Meningitis1
  • Milner Centre for Evolution1
  • National Institute for Communicable Diseases1
  • School of Electrical & Information Engineering1
  • School of Pathology1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across the same disease area as Erythromycin in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.